Recro Pharma, Inc. (NASDAQ: REPH) Stock Competitors & Peer Comparison
See REPH's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for REPH and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| REPH | $2.09 | -0.48% | 177.4M | -8.04 | -$0.26 | N/A |
| TAK | $17.98 | -0.28% | 57.2B | 12.93 | $1.39 | +3.50% |
| HLN | $10.03 | -0.79% | 44.2B | 18.72 | $0.54 | +1.23% |
| TEVA | $36.05 | -1.07% | 42B | 12.30 | $2.93 | N/A |
| ZTS | $77.10 | -0.31% | 32.3B | 11.72 | $6.58 | +2.73% |
| VTRS | $16.51 | +1.04% | 19.2B | 6.55 | $2.52 | +2.92% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.92 | -0.79% | 11.9B | 22.56 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.13 | -0.41% | 10.1B | 19.87 | $0.61 | +0.68% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
REPH vs TAK Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TAK has a market cap of 57.2B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while TAK trades at $17.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TAK's P/E ratio is 12.93. In terms of profitability, REPH's ROE is -0.22%, compared to TAK's ROE of +0.02%. Regarding short-term risk, REPH is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for REPH.Check TAK's competition here
Haleon plc (NYSE: HLN)
REPH vs HLN Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, HLN has a market cap of 44.2B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while HLN trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas HLN's P/E ratio is 18.72. In terms of profitability, REPH's ROE is -0.22%, compared to HLN's ROE of +0.17%. Regarding short-term risk, REPH is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for REPH.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
REPH vs TEVA Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TEVA has a market cap of 42B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while TEVA trades at $36.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TEVA's P/E ratio is 12.30. In terms of profitability, REPH's ROE is -0.22%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, REPH is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for REPH.Check TEVA's competition here
Zoetis Inc. (NYSE: ZTS)
REPH vs ZTS Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ZTS has a market cap of 32.3B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ZTS trades at $77.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ZTS's P/E ratio is 11.72. In terms of profitability, REPH's ROE is -0.22%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, REPH is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
REPH vs VTRS Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, VTRS has a market cap of 19.2B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while VTRS trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas VTRS's P/E ratio is 6.55. In terms of profitability, REPH's ROE is -0.22%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, REPH is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for REPH.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
REPH vs ITCI Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ITCI's P/E ratio is -180.64. In terms of profitability, REPH's ROE is -0.22%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, REPH is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
REPH vs ELAN Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ELAN has a market cap of 11.9B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ELAN trades at $23.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ELAN's P/E ratio is 22.56. In terms of profitability, REPH's ROE is -0.22%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, REPH is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
REPH vs CTLT Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas CTLT's P/E ratio is -27.84. In terms of profitability, REPH's ROE is -0.22%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, REPH is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for REPH.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
REPH vs RDY Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, RDY has a market cap of 10.1B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while RDY trades at $12.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas RDY's P/E ratio is 19.87. In terms of profitability, REPH's ROE is -0.22%, compared to RDY's ROE of +0.09%. Regarding short-term risk, REPH is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for REPH.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
REPH vs ALKS Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ALKS has a market cap of 7.9B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ALKS trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ALKS's P/E ratio is 49.46. In terms of profitability, REPH's ROE is -0.22%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, REPH is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
REPH vs LNTH Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while LNTH trades at $100.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas LNTH's P/E ratio is 16.97. In terms of profitability, REPH's ROE is -0.22%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, REPH is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for REPH.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
REPH vs AMRX Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while AMRX trades at $17.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas AMRX's P/E ratio is 19.41. In terms of profitability, REPH's ROE is -0.22%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, REPH is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for REPH.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
REPH vs INDV Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, INDV has a market cap of 4.4B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while INDV trades at $34.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas INDV's P/E ratio is 9.57. In terms of profitability, REPH's ROE is -0.22%, compared to INDV's ROE of -2.16%. Regarding short-term risk, REPH is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for REPH.Check INDV's competition here
Alvotech (NASDAQ: ALVOW)
REPH vs ALVOW Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ALVOW trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ALVOW's P/E ratio is 47.36. In terms of profitability, REPH's ROE is -0.22%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, REPH is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for REPH.Check ALVOW's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
REPH vs RGC Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while RGC trades at $5.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas RGC's P/E ratio is -388.03. In terms of profitability, REPH's ROE is -0.22%, compared to RGC's ROE of -2.32%. Regarding short-term risk, REPH is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for REPH.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
REPH vs SUPN Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while SUPN trades at $44.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas SUPN's P/E ratio is 14.45. In terms of profitability, REPH's ROE is -0.22%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, REPH is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for REPH.Check SUPN's competition here
Bausch Health Companies Inc. (NYSE: BHC)
REPH vs BHC Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while BHC trades at $6.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas BHC's P/E ratio is 1.62. In terms of profitability, REPH's ROE is -0.22%, compared to BHC's ROE of +0.89%. Regarding short-term risk, REPH is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for REPH.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
REPH vs DCPH Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas DCPH's P/E ratio is -11.58. In terms of profitability, REPH's ROE is -0.22%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, REPH is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for REPH.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
REPH vs AVDL Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, REPH's ROE is -0.22%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, REPH is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for REPH.Check AVDL's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
REPH vs HCM Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while HCM trades at $12.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas HCM's P/E ratio is 4.54. In terms of profitability, REPH's ROE is -0.22%, compared to HCM's ROE of +0.01%. Regarding short-term risk, REPH is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for REPH.Check HCM's competition here
Perrigo Company plc (NYSE: PRGO)
REPH vs PRGO Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while PRGO trades at $14.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas PRGO's P/E ratio is 5.86. In terms of profitability, REPH's ROE is -0.22%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, REPH is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for REPH.Check PRGO's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
REPH vs TRLV Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while TRLV trades at $11.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TRLV's P/E ratio is -4.68. In terms of profitability, REPH's ROE is -0.22%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, REPH is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for REPH.Check TRLV's competition here
Embecta Corp. (NASDAQ: EMBCV)
REPH vs EMBCV Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas EMBCV's P/E ratio is N/A. In terms of profitability, REPH's ROE is -0.22%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, REPH is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for REPH.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
REPH vs DVAX Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas DVAX's P/E ratio is -41.89. In terms of profitability, REPH's ROE is -0.22%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, REPH is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for REPH.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
REPH vs ALVO Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ALVO trades at $5.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ALVO's P/E ratio is -15.26. In terms of profitability, REPH's ROE is -0.22%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, REPH is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ALVO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
REPH vs ANIP Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ANIP trades at $73.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ANIP's P/E ratio is 8.91. In terms of profitability, REPH's ROE is -0.22%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, REPH is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ANIP's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
REPH vs ETON Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ETON has a market cap of 1.7B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ETON trades at $60.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ETON's P/E ratio is 131.39. In terms of profitability, REPH's ROE is -0.22%, compared to ETON's ROE of +0.40%. Regarding short-term risk, REPH is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ETON's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
REPH vs TARO Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TARO's P/E ratio is 30.05. In terms of profitability, REPH's ROE is -0.22%, compared to TARO's ROE of +0.03%. Regarding short-term risk, REPH is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for REPH.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
REPH vs PAHC Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, PAHC has a market cap of 1.5B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while PAHC trades at $37.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas PAHC's P/E ratio is 12.88. In terms of profitability, REPH's ROE is -0.22%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, REPH is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for REPH.Check PAHC's competition here
Harrow Health, Inc. (NASDAQ: HROW)
REPH vs HROW Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while HROW trades at $36.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas HROW's P/E ratio is -37.28. In terms of profitability, REPH's ROE is -0.22%, compared to HROW's ROE of -1.04%. Regarding short-term risk, REPH is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for REPH.Check HROW's competition here
Cronos Group Inc. (NASDAQ: CRON)
REPH vs CRON Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while CRON trades at $3.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas CRON's P/E ratio is 32.00. In terms of profitability, REPH's ROE is -0.22%, compared to CRON's ROE of +0.06%. Regarding short-term risk, REPH is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for REPH.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
REPH vs PCRX Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while PCRX trades at $25.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas PCRX's P/E ratio is 9.96. In terms of profitability, REPH's ROE is -0.22%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, REPH is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for REPH.Check PCRX's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
REPH vs AMPH Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, AMPH has a market cap of 993.4M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while AMPH trades at $22.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas AMPH's P/E ratio is 7.69. In terms of profitability, REPH's ROE is -0.22%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, REPH is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for REPH.Check AMPH's competition here
PetIQ, Inc. (NASDAQ: PETQ)
REPH vs PETQ Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas PETQ's P/E ratio is 83.73. In terms of profitability, REPH's ROE is -0.22%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, REPH is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for REPH.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
REPH vs COLL Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, COLL has a market cap of 798.2M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while COLL trades at $24.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas COLL's P/E ratio is 3.09. In terms of profitability, REPH's ROE is -0.22%, compared to COLL's ROE of +0.16%. Regarding short-term risk, REPH is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for REPH.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
REPH vs IRWD Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, IRWD has a market cap of 699.6M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while IRWD trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas IRWD's P/E ratio is 5.45. In terms of profitability, REPH's ROE is -0.22%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, REPH is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for REPH.Check IRWD's competition here
Glass House Brands Inc (NYSE: GLAS)
REPH vs GLAS Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, GLAS has a market cap of 691M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while GLAS trades at $8.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas GLAS's P/E ratio is -15.95. In terms of profitability, REPH's ROE is -0.22%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, REPH is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for REPH.Check GLAS's competition here
Evotec SE (NASDAQ: EVO)
REPH vs EVO Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, EVO has a market cap of 667.9M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while EVO trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas EVO's P/E ratio is -2.65. In terms of profitability, REPH's ROE is -0.22%, compared to EVO's ROE of -0.27%. Regarding short-term risk, REPH is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for REPH.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
REPH vs AQST Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, AQST has a market cap of 641.1M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while AQST trades at $5.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas AQST's P/E ratio is -7.86. In terms of profitability, REPH's ROE is -0.22%, compared to AQST's ROE of +2.44%. Regarding short-term risk, REPH is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for REPH.Check AQST's competition here
Evolus, Inc. (NASDAQ: EOLS)
REPH vs EOLS Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, EOLS has a market cap of 598.6M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while EOLS trades at $9.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas EOLS's P/E ratio is -28.79. In terms of profitability, REPH's ROE is -0.22%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, REPH is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for REPH.Check EOLS's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
REPH vs BDSI Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas BDSI's P/E ratio is 6.82. In terms of profitability, REPH's ROE is -0.22%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, REPH is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for REPH.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
REPH vs TLRY Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TLRY has a market cap of 511.1M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while TLRY trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TLRY's P/E ratio is -4.22. In terms of profitability, REPH's ROE is -0.22%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, REPH is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for REPH.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
REPH vs KMDA Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, KMDA has a market cap of 474.8M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while KMDA trades at $8.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas KMDA's P/E ratio is 21.66. In terms of profitability, REPH's ROE is -0.22%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, REPH is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for REPH.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
REPH vs CGC Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, CGC has a market cap of 420M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while CGC trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas CGC's P/E ratio is -0.60. In terms of profitability, REPH's ROE is -0.22%, compared to CGC's ROE of -0.33%. Regarding short-term risk, REPH is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for REPH.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
REPH vs TKNO Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TKNO has a market cap of 384.9M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while TKNO trades at $7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TKNO's P/E ratio is -23.16. In terms of profitability, REPH's ROE is -0.22%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, REPH is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for REPH.Check TKNO's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
REPH vs EBS Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, EBS has a market cap of 314.2M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while EBS trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas EBS's P/E ratio is 4.23. In terms of profitability, REPH's ROE is -0.22%, compared to EBS's ROE of -0.36%. Regarding short-term risk, REPH is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for REPH.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
REPH vs ALIM Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ALIM's P/E ratio is 5.28. In terms of profitability, REPH's ROE is -0.22%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, REPH is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
REPH vs LNDC Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas LNDC's P/E ratio is -4.04. In terms of profitability, REPH's ROE is -0.22%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, REPH is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for REPH.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
REPH vs ACB Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ACB has a market cap of 250.9M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ACB trades at $4.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ACB's P/E ratio is -8.27. In terms of profitability, REPH's ROE is -0.22%, compared to ACB's ROE of -0.21%. Regarding short-term risk, REPH is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ACB's competition here
Shineco, Inc. (NASDAQ: TYHT)
REPH vs TYHT Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TYHT's P/E ratio is -1.61. In terms of profitability, REPH's ROE is -0.22%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, REPH is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for REPH.Check TYHT's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
REPH vs CRDL Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, CRDL has a market cap of 227.7M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while CRDL trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas CRDL's P/E ratio is -7.87. In terms of profitability, REPH's ROE is -0.22%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, REPH is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for REPH.Check CRDL's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
REPH vs SIGA Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, SIGA has a market cap of 225.2M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while SIGA trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas SIGA's P/E ratio is 11.63. In terms of profitability, REPH's ROE is -0.22%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, REPH is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for REPH.Check SIGA's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
REPH vs ORGO Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ORGO has a market cap of 221.3M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ORGO trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ORGO's P/E ratio is 57.33. In terms of profitability, REPH's ROE is -0.22%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, REPH is more volatile compared to ORGO. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ORGO's competition here
Journey Medical Corporation (NASDAQ: DERM)
REPH vs DERM Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, DERM has a market cap of 203.9M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while DERM trades at $7.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas DERM's P/E ratio is -20.03. In terms of profitability, REPH's ROE is -0.22%, compared to DERM's ROE of -0.20%. Regarding short-term risk, REPH is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for REPH.Check DERM's competition here
Organigram Global Inc. (NASDAQ: OGI)
REPH vs OGI Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, OGI has a market cap of 170.3M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while OGI trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas OGI's P/E ratio is 2.72. In terms of profitability, REPH's ROE is -0.22%, compared to OGI's ROE of +0.21%. Regarding short-term risk, REPH is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for REPH.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
REPH vs LFCR Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, LFCR has a market cap of 167.3M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while LFCR trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas LFCR's P/E ratio is -4.17. In terms of profitability, REPH's ROE is -0.22%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, REPH is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for REPH.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
REPH vs THTX Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas THTX's P/E ratio is -28.83. In terms of profitability, REPH's ROE is -0.22%, compared to THTX's ROE of +0.17%. Regarding short-term risk, REPH is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for REPH.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
REPH vs ASRT Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ASRT's P/E ratio is -7.10. In terms of profitability, REPH's ROE is -0.22%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, REPH is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
REPH vs SCTL Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas SCTL's P/E ratio is -7.86. In terms of profitability, REPH's ROE is -0.22%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, REPH is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for REPH.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
REPH vs BGM Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, BGM has a market cap of 103.5M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while BGM trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas BGM's P/E ratio is -0.94. In terms of profitability, REPH's ROE is -0.22%, compared to BGM's ROE of -0.05%. Regarding short-term risk, REPH is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for REPH.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
REPH vs PROC Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas PROC's P/E ratio is 1.53. In terms of profitability, REPH's ROE is -0.22%, compared to PROC's ROE of -2.22%. Regarding short-term risk, REPH is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for REPH.Check PROC's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
REPH vs CPIX Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, CPIX has a market cap of 100.2M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while CPIX trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas CPIX's P/E ratio is -16.73. In terms of profitability, REPH's ROE is -0.22%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, REPH is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for REPH.Check CPIX's competition here
OptiNose, Inc. (NASDAQ: OPTN)
REPH vs OPTN Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas OPTN's P/E ratio is -4.42. In terms of profitability, REPH's ROE is -0.22%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, REPH is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for REPH.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
REPH vs ZOM Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ZOM's P/E ratio is -1.62. In terms of profitability, REPH's ROE is -0.22%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, REPH is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
REPH vs GRVI Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas GRVI's P/E ratio is 26.05. In terms of profitability, REPH's ROE is -0.22%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, REPH is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for REPH.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
REPH vs ZYBT Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ZYBT has a market cap of 82M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ZYBT trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ZYBT's P/E ratio is -7.86. In terms of profitability, REPH's ROE is -0.22%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, REPH is more volatile compared to ZYBT. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
REPH vs ZYNE Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, REPH's ROE is -0.22%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, REPH is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ZYNE's competition here
InterCure Ltd. (NASDAQ: INCR)
REPH vs INCR Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, INCR has a market cap of 68.2M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while INCR trades at $5.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas INCR's P/E ratio is -13.30. In terms of profitability, REPH's ROE is -0.22%, compared to INCR's ROE of -0.09%. Regarding short-term risk, REPH is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for REPH.Check INCR's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
REPH vs SSIC Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas SSIC's P/E ratio is 11.93. In terms of profitability, REPH's ROE is -0.22%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, REPH is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for REPH.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
REPH vs TLPH Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TLPH has a market cap of 61.8M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while TLPH trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TLPH's P/E ratio is -3.84. In terms of profitability, REPH's ROE is -0.22%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, REPH is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for REPH.Check TLPH's competition here
The Valens Company Inc. (NASDAQ: VLNS)
REPH vs VLNS Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas VLNS's P/E ratio is -1.03. In terms of profitability, REPH's ROE is -0.22%, compared to VLNS's ROE of N/A. Regarding short-term risk, REPH is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for REPH.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
REPH vs DRRX Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas DRRX's P/E ratio is -4.44. In terms of profitability, REPH's ROE is -0.22%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, REPH is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for REPH.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
REPH vs JUPW Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas JUPW's P/E ratio is -2.41. In terms of profitability, REPH's ROE is -0.22%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, REPH is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for REPH.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
REPH vs QLI Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas QLI's P/E ratio is -4.92. In terms of profitability, REPH's ROE is -0.22%, compared to QLI's ROE of -0.16%. Regarding short-term risk, REPH is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for REPH.Check QLI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
REPH vs CPHI Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, CPHI has a market cap of 35.9M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while CPHI trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas CPHI's P/E ratio is -2.06. In terms of profitability, REPH's ROE is -0.22%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, REPH is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for REPH.Check CPHI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
REPH vs RMTI Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, RMTI has a market cap of 32.8M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while RMTI trades at $8.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas RMTI's P/E ratio is -6.20. In terms of profitability, REPH's ROE is -0.22%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, REPH is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for REPH.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
REPH vs HEXO Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas HEXO's P/E ratio is -0.26. In terms of profitability, REPH's ROE is -0.22%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, REPH is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for REPH.Check HEXO's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
REPH vs TXMD Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TXMD has a market cap of 25.2M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while TXMD trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TXMD's P/E ratio is 111.05. In terms of profitability, REPH's ROE is -0.22%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, REPH is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for REPH.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
REPH vs AYTU Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, AYTU has a market cap of 24.6M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while AYTU trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas AYTU's P/E ratio is -1.19. In terms of profitability, REPH's ROE is -0.22%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, REPH is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for REPH.Check AYTU's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
REPH vs CYTH Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas CYTH's P/E ratio is -0.80. In terms of profitability, REPH's ROE is -0.22%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, REPH is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for REPH.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
REPH vs EVOK Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas EVOK's P/E ratio is -7.97. In terms of profitability, REPH's ROE is -0.22%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, REPH is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for REPH.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
REPH vs OPTH Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, OPTH has a market cap of 15.9M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while OPTH trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas OPTH's P/E ratio is -18.04. In terms of profitability, REPH's ROE is -0.22%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, REPH is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for REPH.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
REPH vs ACRX Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ACRX's P/E ratio is -0.31. In terms of profitability, REPH's ROE is -0.22%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, REPH is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for REPH.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
REPH vs CABR Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, CABR has a market cap of 12.2M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while CABR trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas CABR's P/E ratio is -2.39. In terms of profitability, REPH's ROE is -0.22%, compared to CABR's ROE of -3.86%. Regarding short-term risk, REPH is more volatile compared to CABR. This indicates higher risk in terms of short-term price fluctuations for REPH.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
REPH vs AGRX Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas AGRX's P/E ratio is -0.89. In terms of profitability, REPH's ROE is -0.22%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, REPH is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for REPH.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
REPH vs NLTX Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas NLTX's P/E ratio is -0.28. In terms of profitability, REPH's ROE is -0.22%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, REPH is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for REPH.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
REPH vs LCI Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas LCI's P/E ratio is -0.04. In terms of profitability, REPH's ROE is -0.22%, compared to LCI's ROE of +1.66%. Regarding short-term risk, REPH is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for REPH.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
REPH vs ADMP Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ADMP's P/E ratio is -0.08. In terms of profitability, REPH's ROE is -0.22%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, REPH is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
REPH vs YCBD Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, YCBD has a market cap of 5.1M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while YCBD trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas YCBD's P/E ratio is -1.21. In terms of profitability, REPH's ROE is -0.22%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, REPH is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for REPH.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
REPH vs GELS Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, GELS has a market cap of 5M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while GELS trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas GELS's P/E ratio is -1.10. In terms of profitability, REPH's ROE is -0.22%, compared to GELS's ROE of -0.25%. Regarding short-term risk, REPH is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for REPH.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
REPH vs MNK Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas MNK's P/E ratio is -0.44. In terms of profitability, REPH's ROE is -0.22%, compared to MNK's ROE of -0.36%. Regarding short-term risk, REPH is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for REPH.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
REPH vs FLGC Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas FLGC's P/E ratio is -0.19. In terms of profitability, REPH's ROE is -0.22%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, REPH is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for REPH.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
REPH vs UPC Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, UPC has a market cap of 2.9M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while UPC trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas UPC's P/E ratio is -0.57. In terms of profitability, REPH's ROE is -0.22%, compared to UPC's ROE of -0.03%. Regarding short-term risk, REPH is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for REPH.Check UPC's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
REPH vs RDHL Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, RDHL has a market cap of 2.9M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while RDHL trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas RDHL's P/E ratio is 0.18. In terms of profitability, REPH's ROE is -0.22%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, REPH is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for REPH.Check RDHL's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
REPH vs SBFM Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, SBFM has a market cap of 2.7M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while SBFM trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas SBFM's P/E ratio is -0.18. In terms of profitability, REPH's ROE is -0.22%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, REPH is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for REPH.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
REPH vs PLXP Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas PLXP's P/E ratio is -0.22. In terms of profitability, REPH's ROE is -0.22%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, REPH is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for REPH.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
REPH vs ATNX Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ATNX's P/E ratio is -0.02. In terms of profitability, REPH's ROE is -0.22%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, REPH is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for REPH.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
REPH vs SNOA Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while SNOA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas SNOA's P/E ratio is -1.09. In terms of profitability, REPH's ROE is -0.22%, compared to SNOA's ROE of -0.46%. Regarding short-term risk, REPH is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for REPH.Check SNOA's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
REPH vs SHPH Comparison September 2026
Recro Pharma, Inc. (NASDAQ: REPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, SHPH has a market cap of 2.1M. Regarding current trading prices, REPH is priced at $2.09 on the NASDAQ, while SHPH trades at $3.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas SHPH's P/E ratio is -0.17. In terms of profitability, REPH's ROE is -0.22%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, REPH is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for REPH.Check SHPH's competition here